On Monday, Shares of Exelon Corporation (NYSE:EXC), lost -1.06% to $32.65.
The Baltimore Ravens declared that they have named Constellation, a partner of Exelon Corporation and a leading competitive retail energy supplier, their “Preferred Energy Choice.” The designation comes as part of a multi-year sponsorship renewal agreement that gives Constellation exclusive naming rights of the 300 and 400 suite levels at M&T Bank Stadium, and comprises signage throughout those levels. This is the first time that the Ravens have welcomed a corporate sponsor at the suite level of M&T Bank Stadium.
“The Ravens have enjoyed a long relationship with Constellation that has allowed us to make a positive difference in our community and environment,” said Kevin Rochlitz, senior vice president of corporate sales and business development for the Ravens. “We are happy to have their support as we continue our efforts to be a model of sustainability for the NFL and our fans.”
As part of the agreement, Constellation will also serve as the presenting sponsor of the annual “State of the Ravens” event featuring General Manager Ozzie Newsome and Head Coach John Harbaugh.
Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, in addition to wind and solar photovoltaic facilities.
Shares of salesforce.com, inc. (NYSE:CRM), declined -5.74% to $65.18, during its last trading session.
Salesforce declared results for its fiscal second quarter ended July 31, 2015.
Salesforce delivered the following results for its fiscal second quarter 2016:
- Revenue: Total Q2 revenue was $1.63 billion, an enhance of 24% year-over-year, and 28% in constant currency. Subscription and support revenues were $1.52 billion, an enhance of 23% year-over-year. Professional services and other revenues were $113 million, an enhance of 32% year-over-year.
- Earnings per Share: Q2 GAAP earnings per share was about $0.00, and non-GAAP diluted earnings per share was $0.19.
- Cash: Cash generated from operations for the fiscal second quarter was $304 million, an enhance of 24% year-over-year. Total cash, cash equivalents and marketable securities finished the quarter at $2.07 billion.
- Deferred Revenue: Deferred revenue on the balance sheet as of July 31, 2015 was $3.03 billion, an enhance of 29% year-over-year, and 33% in constant currency. Unbilled deferred revenue, representing business that is contracted but unbilled and off balance sheet, ended the quarter at about $6.2 billion, up 24% year-over-year.
- As of August 20, 2015, the company is initiating revenue, earnings per share, and deferred revenue guidance for its third quarter of fiscal year 2016. In addition, the company is raising its full fiscal year 2016 revenue and earnings per share guidance formerly offered on May 20, 2015.
- Q3 FY16 Guidance: Revenue for the company’s third fiscal quarter is projected to be about $1.69 billion to $1.70 billion, an enhance of 22% to 23% year-over-year.
- GAAP loss per share is predictable to be in the range of ($0.02) to ($0.01), while diluted non-GAAP earnings per share is predictable to be in the range of $0.18 to $0.19.
- On balance sheet deferred revenue growth for the third fiscal quarter is projected to be in the mid-20s percentages year-over-year.
- Full Year FY16 Guidance: Revenue for the company’s full fiscal year 2016 is projected to be about $6.60 billion to $6.625 billion, an enhance of 23% year-over-year.
- GAAP loss per share is predictable to be in the range of ($0.17) to ($0.15), while diluted non-GAAP earnings per share is predictable to be in the range of $0.70 to $0.72.
- Operating cash flow growth for the company’s full fiscal year 2016 is projected to be about 24% to 25% year-over-year.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship administration to various businesses and industries worldwide. The company offers enterprise cloud computing apps and platform services, counting Sales Cloud for sales force automation, which enables companies to store data, access accurate customer and prospect information, track leads and progress, forecast opportunities, and collaborate around any sale on desktop and mobile devices; Service Cloud that enables companies to connect address customers service and support needs; and Marketing Cloud, which enables companies to map customer journeys to digital marketing interactions through email, mobile, social, Web, and connected products.
Finally, Relypsa Inc (NASDAQ:RLYP), ended its last trade with -4.04% loss, and closed at $22.79.
Relypsa, declared they have reached an exclusive partnership to commercialize Patiromer for Oral Suspension (Patiromer FOS), Relypsa’s investigational medicine for the treatment of hyperkalemia.
Under the terms of the agreement, Relypsa will receive an upfront cash payment of $40 million and will be eligible to receive payments of up to $125 million upon achieving certain regulatory and sales based milestones. In addition, Relypsa will receive tiered double-digit royalties on net sales of Patiromer FOS in the licensed territories. VFMCRP will obtain an exclusive marketing right from Relypsa in worldwide territories except the United States and Japan, where Relypsa retains all commercial rights. Relypsa and VFMCRP will collaborate on ongoing development of Patiromer FOS, counting submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA).
Patiromer FOS is an oral potassium binder being developed for the treatment of hyperkalemia, a potentially life-threatening condition defined as abnormally elevated levels of potassium in the blood. Hyperkalemia occurs most frequently in patients with chronic kidney disease (CKD) and heart failure. A New Drug Application (NDA) for Patiromer FOS for the treatment of hyperkalemia is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of October 21, 2015. A MAA for Patiromer FOS is predictable to be presented with the EMA in the first half of 2016.
Relypsa, Inc., a biopharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
